Ira Gantz
About
Ira Gantz is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery.
According to data from OpenAlex, Ira Gantz has authored 24 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Endocrinology, Diabetes and Metabolism, 16 papers in Molecular Biology and 5 papers in Surgery. Recurrent topics in Ira Gantz's work include Diabetes Treatment and Management (18 papers), Metabolism, Diabetes, and Cancer (15 papers) and Gastric Cancer Management and Outcomes (5 papers). Ira Gantz is often cited by papers focused on Diabetes Treatment and Management (18 papers), Metabolism, Diabetes, and Cancer (15 papers) and Gastric Cancer Management and Outcomes (5 papers). Ira Gantz collaborates with scholars based in United States, Sweden and Canada. Ira Gantz's co-authors include Steven G. Terra, David Z.I. Cherney, Richard E. Pratley, Francesco Cosentino, Darren K. McGuire, Weichung Shih, B Charbonnel, Christopher P. Cannon, Urszula Masiukiewicz and Susan Huyck and has published in prestigious journals such as New England Journal of Medicine, Circulation and The Journal of Clinical Endocrinology & Metabolism.
In The Last Decade
Ira Gantz
22 papers receiving 2.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ira Gantz United States | 12 | 1.8k | 767 | 694 | 506 | 382 | 24 | 2.3k | ||
| Nima Soleymanlou Canada | 16 | 2.1k 1.1× | 693 0.9× | 1.3k 1.8× | 283 0.6× | 248 0.6× | 27 | 3.0k | ||
| Elena Henkel Germany | 16 | 1.6k 0.9× | 673 0.9× | 347 0.5× | 529 1.0× | 182 0.5× | 34 | 2.3k | ||
| Egon Pfarr Germany | 12 | 1.5k 0.8× | 497 0.6× | 489 0.7× | 421 0.8× | 115 0.3× | 20 | 1.8k | ||
| Amy E. Rudolph United States | 25 | 961 0.5× | 473 0.6× | 887 1.3× | 830 1.6× | 450 1.2× | 40 | 2.3k | ||
| Hiromichi Wakui Japan | 26 | 583 0.3× | 470 0.6× | 278 0.4× | 816 1.6× | 159 0.4× | 125 | 1.9k | ||
| Thomas Idorn Denmark | 19 | 1.6k 0.9× | 498 0.6× | 645 0.9× | 281 0.6× | 169 0.4× | 44 | 2.1k | ||
| Sven Schnaidt Germany | 13 | 1.5k 0.8× | 517 0.7× | 540 0.8× | 622 1.2× | 223 0.6× | 22 | 1.9k | ||
| Wakako Kawarazaki Japan | 18 | 727 0.4× | 571 0.7× | 295 0.4× | 339 0.7× | 199 0.5× | 31 | 1.4k | ||
| Søren Rasmussen Denmark | 27 | 2.6k 1.4× | 951 1.2× | 1.0k 1.5× | 454 0.9× | 169 0.4× | 87 | 3.2k | ||
| Tracey A. Gaspari Australia | 19 | 821 0.4× | 654 0.9× | 267 0.4× | 863 1.7× | 145 0.4× | 47 | 1.7k |
Countries citing papers authored by Ira Gantz
Since
Specialization
Citations
This map shows the geographic impact of Ira Gantz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ira Gantz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ira Gantz more than expected).
Fields of papers citing papers by Ira Gantz
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ira Gantz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ira Gantz. The network helps show where Ira Gantz may publish in the future.
Co-authorship network of co-authors of Ira Gantz
This figure shows the co-authorship network connecting the top 25 collaborators of Ira Gantz. A scholar is included among the top collaborators of Ira Gantz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ira Gantz. Ira Gantz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
2.
Dagogo‐Jack, Samuel, Robert Frederich, Jie Liu, et al.. (2023). Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV. The Journal of Clinical Endocrinology & Metabolism. 108(8). 2042–2051.
3.
Pandey, Ambarish, Ahmed A. Kolkailah, Francesco Cosentino, et al.. (2023). Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial. European Heart Journal. 44(48). 5163–5166.
4.
Dagogo‐Jack, Samuel, Christopher P. Cannon, David Z.I. Cherney, et al.. (2022). Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from VERTIS CV . Diabetes Obesity and Metabolism. 24(7). 1245–1254.
5.
Strojek, Krzysztof, A. Shekhar Pandey, Shuai Wang, et al.. (2021). Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV. Diabetes Therapy. 12(4). 1175–1192.
6.
Lingvay, Ildiko, et al.. (2021). Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy. Diabetes Obesity and Metabolism. 23(7). 1640–1651.
7.
Budoff, Matthew J., Timothy M. E. Davis, Robert Frederich, et al.. (2021). Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV. Diabetes Therapy. 12(5). 1279–1297.
8.
Dagogo‐Jack, Samuel, Richard E. Pratley, David Z.I. Cherney, et al.. (2021). Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial. BMJ Open Diabetes Research & Care. 9(1). e002484–e002484.
9.
Dagogo‐Jack, Samuel, Robert Frederich, B Charbonnel, et al.. (2021). 785-P: Ertugliflozin (ERTU) Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients with Type 2 Diabetes (T2D): An Analysis From VERTIS CV. Diabetes. 70(Supplement_1).
10.
Cosentino, Francesco, Christopher P. Cannon, David Z.I. Cherney, et al.. (2020). Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease. Circulation. 142(23). 2205–2215.
11.
Wang, Tongtong, Shrita M. Patel, Anne Hickman, et al.. (2020). SGLT2 Inhibitors and the Risk of Hospitalization for Fournier’s Gangrene: A Nested Case–Control Study. Diabetes Therapy. 11(3). 711–723.
12.
Cherney, David Z.I., Hiddo J.L. Heerspink, Robert Frederich, et al.. (2020). Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials. Diabetologia. 63(6). 1128–1140.
13.
Patel, Shrita M., Anne Hickman, Robert Frederich, et al.. (2020). Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials. Diabetes Therapy. 11(6). 1347–1367.
14.
McGuire, Darren K., Weichung Shih, Francesco Cosentino, et al.. (2020). Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes. JAMA Cardiology. 6(2). 148–148.
15.
Liu, Jie, Lisa Tarasenko, Annpey Pong, et al.. (2020). Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus. Current Medical Research and Opinion. 36(8). 1277–1284.
16.
Cannon, Christopher P., Richard E. Pratley, Samuel Dagogo‐Jack, et al.. (2020). Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. New England Journal of Medicine. 383(15). 1425–1435.
17.
Liu, Jie, Shrita M. Patel, Nilo B. Cater, et al.. (2019). Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus. Diabetes Obesity and Metabolism. 22(4). 574–582.
18.
Gantz, Ira, et al.. (1996). Molecular cloning of a novel receptor (CMKLR1) with homology to the chemotactic factor receptors. Cytogenetic and Genome Research. 74(4). 286–290.
19.
Gantz, Ira, Tadataka Yamada, Takao Tashiro, et al.. (1994). Mapping of the Gene Encoding the Melanocortin-1 (α-Melanocyte Stimulating Hormone) Receptor (MC1R) to Human Chromosome 16q24.3 by Fluorescence in Situ Hybridization. Genomics. 19(2). 394–395.
20.
Gantz, Ira, Takao Tashiro, Yoshitaka Konda, et al.. (1993). Localization of the Genes Encoding the Melanocortin-2 (Adrenocorticotropic Hormone) and Melanocortin-3 Receptors to Chromosomes 18p11.2 and 20q13.2-q13.3 by Fluorescence in Situ Hybridization. Genomics. 18(1). 166–167.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Nima Soleymanlou Breakdown of academic impact, for papers by Elena Henkel Breakdown of academic impact, for papers by Egon Pfarr Breakdown of academic impact, for papers by Amy E. Rudolph Breakdown of academic impact, for papers by Hiromichi Wakui Breakdown of academic impact, for papers by Thomas Idorn Breakdown of academic impact, for papers by Sven Schnaidt Breakdown of academic impact, for papers by Wakako Kawarazaki Breakdown of academic impact, for papers by Søren Rasmussen Breakdown of academic impact, for papers by Tracey A. Gaspari